跳至主要内容
临床试验/NCT05141071
NCT05141071已完成2 期

Effect of Ivabradine on Microcirculation and Cardiac Output in Patients Diagnosed With Septic Shock (Open-label Randomized Controlled Study)

Cairo University1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2021年11月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
44
试验地点
1
主要终点
Microvascular flow index

研究概览

简要总结

Persistent tachycardia in sepsis or multi-organ dysfunction syndrome (MODS) is an ominous sign. This usually comes under control with judicious use of antibiotics, fluid resuscitation, sedation. Uncontrolled tachycardia in systemic inflammatory response syndrome and sepsis deprives the heart muscle of oxygen. As it progresses, insufficient heart muscle nutrition eventually leads to myocardial dysfunction. It can also present as heart failure. In acute coronary syndromes, beta blockers are used to control heart rate. However in MODS, it cannot be used due to hemodynamic instability and worsened myocardial function.

Sinoatrial (SA) myocytes are the pacemaker cells in the heart. Pacemaker activity involves several ionic currents that influences spontaneous depolarization of SA node including I(f) current. The word I(f) means funny, because this current has unusual properties as compared with other currents known at the time of its discovery. It is one of the most important ionic current for regulating pacemaker activity in SA node.

Ivabradine is an I(f) current inhibitor in SA node. Currently, it is the only agent shown to clinically lower heart rate with no negative inotropism or effects on conduction and contractility.so usage of Ivabradine to control tachycardia in patients with septic shock may help to improve myocardial filling and cardiac output.

Marcos L.Miranda et al. found that Ivabradine was effective in reducing microvascular derangements evoked by experimental sepsis, which was accompanied by less organ dysfunction. These results suggest that ivabradine yields beneficial effects on the microcirculation of septic animals.

No data found on effect of Ivabradine on the microcirculation of human. In this study the investigators will investigate the effect of Ivabradine on perfusion in capillary circulation using Cytocam video microscope, Braedius®.

详细描述

All patients will be monitored with non-invasive arterial blood pressure, five-lead electrocardiography (ECG), pulse oximetry, and invasive arterial pressure (AP) obtained from a radial arterial catheter.

Upon ICU admission, according to the investigators' institutional protocol, fluid responsiveness will be done for all enrolled patients to determine the need for fluid therapy (fluid responsiveness is defined as an increase in the stroke volume (SV) by 15% after infusing 500 ml crystalloids). Fluid boluses will be repeated till the patients become fluid unresponsiveness. If mean arterial pressure (MAP) remained < 65 mm Hg after administration of the initial fluid bolus, norepinephrine infusion will be titrated to maintain MAP ≥ 65 mmHg.

After establishment of blood pressure and normovolemia, the patient will receive either placebo or Ivabradine according to the group randomization.

Assessment of microcirculation:

Sublingual microcirculatory measurements will be performed with an incident dark-field illumination device Cytocam- incident dark-field illumination (IDF), Braedius Medical, Huizen, Netherlands). The new technology Cytocam-IDF imaging device consists of a pen-like probe incorporating IDF illumination with a set of high-resolution lenses projecting images on to a computer-controlled image sensor synchronized with a short-pulsed illumination light. Flow characteristics of the microvasculature will be quantified using the microvascular flow index (MFI), a semiquantitative technique consistent with recommendations from a consensus conference on microcirculatory image analysis in human subjects.The image is divided into four quadrants and the vessels <20 μ m diameter are assigned a score based on the predominant flow characteristics of the vessels in that quadrant (0 = absent flow; 1 = intermittent; 2 = sluggish; 3 = normal). The values in each quadrant will be averaged to give an MFI for each sublingual site at each time point. To determine heterogeneity of perfusion, the flow heterogeneity index will be calculated as the highest MFI minus the lowest MFI divided by the mean MFI. A quantitative measurement of the total vessel density (TVD), perfused vessel density (PVD), and proportion of perfused vessels (PPV), will also be taken automatically with dedicated software (Cytocam video microscope, Braedius®, Netherlands). The observer will be well-trained and experienced with offline analysis. On all videos, post-process contrast enhancement will be applied. Thereafter videos will be blinded and anonymized so that the observer will not be aware of the used drug.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Ivabradine

Experimental

In the study group, Ivabradine(I) group; patients will receive an enteral Ivabradine (dissolved in distilled water) 5mg twice daily (every 12 hours) via a naso-gastric tube.

干预措施: Ivabradine 5mg Tab (Drug)

Placebo

Placebo Comparator

the control group, Placebo (P) group; patients will receive 50 ml of saline twice daily also via a naso-gastric tube.

干预措施: Placebo (Drug)

结局指标

主要结局

Microvascular flow index

时间窗: 6 hours after administration of Ivabradine or Placebo.

absent (0), intermittent (1), sluggish (2), or normal (3)

次要结局

  • Percentage of perfused vessels(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • Cardiac output(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • Microvascular flow index(Before drug administration and at 1, 12, and 24 hours thereafter.)
  • Heart rate(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • Mean arterial blood pressure(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • Total vessel density(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • Central venous saturation(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • Central venous-arterial blood carbon dioxide partial pressure difference(Before drug administration and at 1, 6,12, and 24 hours thereafter.)
  • ICU length of stay(from the date of patient recruitment till the date of discharge from the ICU or the date of death, assessed up to 28 days)
  • 28 days ICU mortality(28 days after ICU admission)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Amr Kamal Zahran

Lecturer of Anesthesia and Intensive care medicine

Cairo University

研究点 (1)

Loading locations...

相似试验